Title:
PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR DISEASES INVOLVING IDO EXPRESSION
Document Type and Number:
WIPO Patent Application WO/2019/054465
Kind Code:
A1
Abstract:
Provided are a prophylactic and/or therapeutic agent for diseases involving IDO expression and a pharmaceutical composition for treating IDO-positive tumors. The prophylactic and/or therapeutic agent for diseases involving IDO expression and the pharmaceutical composition for treating IDO-positive tumors comprise, as an active ingredient, a compound inhibiting HSP90.
Inventors:
MURAOKA HIROMI (JP)
Application Number:
PCT/JP2018/034092
Publication Date:
March 21, 2019
Filing Date:
September 14, 2018
Export Citation:
Assignee:
TAIHO PHARMACEUTICAL CO LTD (JP)
International Classes:
A61K45/00; A61K31/395; A61K31/4196; A61K31/437; A61K31/52; A61P35/00; A61P35/02; A61P35/04; A61P43/00
Domestic Patent References:
| WO2011004610A1 | 2011-01-13 | |||
| WO2015046498A1 | 2015-04-02 | |||
| WO2016181990A1 | 2016-11-17 | |||
| WO2011004610A1 | 2011-01-13 |
Foreign References:
| JP2015226536A | 2015-12-17 |
Other References:
PROIA, D. A . ET AL.: "Preclinical Activity Profile and Therapeutic Efficacy of the HSP90 Inhibitor Ganetespib in Triple-Negative Breast Cancer", CLIN. CANCER RES., vol. 20, no. 2, 2013, pages 413 - 424, XP055327621, DOI: doi:10.1158/1078-0432.CCR-13-2166
LIN, S. ET AL.: "BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF- kappa B pathway proteins", EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 7, 2014 - 12 March 2014 (2014-03-12), pages 1539 - 1544, XP055582570, ISSN: 1792-0981, DOI: 10.3892/etm.2014.1651
INT. IMMUNOPHARMACOL., vol. 47, 2017, pages 70 - 77
NAT. REV. CANCER, vol. 5, 2005, pages 761 - 772
TRENDS MOL. MED., vol. 10, 2004, pages 283 - 290
CLIN. CANCER RES., vol. 15, 2009, pages 9 - 14
CURR. OPIN. PHARMACOL., vol. 8, 2008, pages 370 - 374
DRUG RESIST. UPDAT., vol. 12, 2009, pages 17 - 27
See also references of EP 3682900A4
LIN, S. ET AL.: "BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF- kappa B pathway proteins", EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 7, 2014 - 12 March 2014 (2014-03-12), pages 1539 - 1544, XP055582570, ISSN: 1792-0981, DOI: 10.3892/etm.2014.1651
INT. IMMUNOPHARMACOL., vol. 47, 2017, pages 70 - 77
NAT. REV. CANCER, vol. 5, 2005, pages 761 - 772
TRENDS MOL. MED., vol. 10, 2004, pages 283 - 290
CLIN. CANCER RES., vol. 15, 2009, pages 9 - 14
CURR. OPIN. PHARMACOL., vol. 8, 2008, pages 370 - 374
DRUG RESIST. UPDAT., vol. 12, 2009, pages 17 - 27
See also references of EP 3682900A4
Attorney, Agent or Firm:
THE PATENT CORPORATE BODY ARUGA PATENT OFFICE (JP)
Download PDF: